NeoGenomics Names Warren Stone CEO, Prelim Q3 Revenue Tops $209M
NEO has more than doubled off its 52-week low of $7.065.
Summary
NeoGenomics announced a planned CEO succession: President & COO Warren Stone becomes CEO effective Jan 4, 2027, with current CEO Tony Zook moving to Executive Chair. Stone's CEO employment agreement includes $850,000 base salary, 100% target bonus, and $8 million annual equity target; Zook's Executive Chair agreement includes $400,000 base salary, 50% target bonus, and $3 million annual equity target. Chair Lynn Tetrault will remain a board member until the 2027 annual meeting. The company also released preliminary Q3 revenue of ~$209M, up from $201.7M in Q2, with NGS revenue up ~28% YoY, and reiterated full-year guidance. This follows the Q2 beat and raised guidance in July, and the recent CMS coverage expansion for RaDaR ST. The leadership transition appears orderly, reducing disruption risk, while the prelim revenue confirms continued growth. Watch for the formal Q3 earnings release for full metrics and any guidance update.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Warren Stone's CEO employment agreement includes $850,000 base salary, 100% target bonus, and $8 million annual equity target; Tony Zook's Executive Chair agreement includes $400,000 base salary, 50% target bonus, and $3 million annual equity target.
At the time of this announcement, NEO was trading at $19.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $7.07 to $20.05. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.